Cargando…

Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)

BACKGROUND: Mismatch repair deficiency (dMMR) is associated with endometrial cancers, yet it remains unknown how this information could be incorporated into adjuvant treatment paradigms. We performed this cohort study to identify the effect of dMMR status on the prognosis of patients with advanced e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Ying, Zhu, Changhua, Song, Xiaoxia, Ruan, Jiugen, Ding, Yao, Chen, Yuan, Yang, Qiujuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962632/ https://www.ncbi.nlm.nih.gov/pubmed/35322001 http://dx.doi.org/10.12659/MSM.934493

Ejemplares similares

An unusual case of microsatellite instability–high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing
por: Han, Bogyeong, et al.
Publicado: (2022)

Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment
por: Song, Yunfeng, et al.
Publicado: (2021)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
por: Oliveira, André F., et al.
Publicado: (2019)

Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation
por: McCarthy, Aoife J, et al.
Publicado: (2018)

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
por: Mulet-Margalef, Núria, et al.
Publicado: (2023)

Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
por: Inamori, Koji, et al.
Publicado: (2021)

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
por: Liu, Fangcen, et al.
Publicado: (2023)

Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
por: Chida, Keigo, et al.
Publicado: (2022)

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system
por: Zhu, Chen, et al.
Publicado: (2023)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
por: Su, Alan, et al.
Publicado: (2023)

High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer
por: Mohamed, Amr, et al.
Publicado: (2021)

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
por: Bui, Quang Loc, et al.
Publicado: (2022)

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm
por: Ozer, Muhammet, et al.
Publicado: (2023)

Should immunohistochemical expression of mismatch repair (MMR) proteins and microsatellite instability (MSI) analysis be routinely performed for poorly differentiated colorectal neuroendocrine carcinomas?
por: Luong, Tu Vinh, et al.
Publicado: (2020)

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
por: Oaknin, Ana, et al.
Publicado: (2022)

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience
por: Tuninetti, Valentina, et al.
Publicado: (2023)

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
por: Fucà, Giovanni, et al.
Publicado: (2022)

Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States
por: Kelkar, Sneha S., et al.
Publicado: (2022)

Mismatch Repair Deficient (dMMR) Colorectal Carcinoma in a Pakistani Cohort: Association With Clinical and Pathological Parameters
por: Hashmi, Atif A, et al.
Publicado: (2023)

Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors
por: Leclerc, Julie, et al.
Publicado: (2021)

Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series
por: Zhou, Chengjing, et al.
Publicado: (2021)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
por: Zhang, Xuan, et al.
Publicado: (2022)

Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy
por: Wu, Hui, et al.
Publicado: (2023)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
por: Loupakis, Fotios, et al.
Publicado: (2019)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis
por: Fan, Shaoqing, et al.
Publicado: (2023)

Pathogenic Insights into DNA Mismatch Repair (MMR) Genes–Proteins and Microsatellite Instability: Focus on Adrenocortical Carcinoma and Beyond
por: Carsote, Mara, et al.
Publicado: (2023)

Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer
por: Ukkola, Iiris, et al.
Publicado: (2021)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
por: Varnier, Romain, et al.
Publicado: (2021)

Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study
por: Zhang, Xuan, et al.
Publicado: (2022)

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
por: Nasca, Vincenzo, et al.
Publicado: (2023)

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
por: Kang, Yoon-Jung, et al.
Publicado: (2022)

High concordance rate of capillary electrophoresis workflow for microsatellite instability analysis and mismatch repair (MMR) immunostaining in colorectal carcinoma
por: Huang, Wenya, et al.
Publicado: (2023)

LDH‐A negatively regulates dMMR in colorectal cancer
por: Zhang, Yongjie, et al.
Publicado: (2021)

The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients
por: Wang, Jie, et al.
Publicado: (2021)

Complete Pathological Response After Neoadjuvant Short‐Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI‐H/dMMR Rectal Cancer
por: Trojan, Jörg, et al.
Publicado: (2021)

Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI‐H/dMMR rectal cancer: A prospective, multicenter, phase Ib study
por: Li, Xiaofen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q9al30657mnsr2vleqmqsrq8e5